Relmada Therapeutics公司近日披露,其针对BCG无应答患者群体开展的3期二线研究,初步的3个月疗效数据预计将在2026年年底获得。这项研究是公司核心管线推进过程中的一个关键节点,其结果备受业界关注。
Relmada Therapeutics公司近日披露,其针对BCG无应答患者群体开展的3期二线研究,初步的3个月疗效数据预计将在2026年年底获得。这项研究是公司核心管线推进过程中的一个关键节点,其结果备受业界关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.